211 related articles for article (PubMed ID: 25414934)
1. Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting.
Digenio A; Karve S; Candrilli SD; Dalal M
Postgrad Med; 2014 Oct; 126(6):49-59. PubMed ID: 25414934
[TBL] [Abstract][Full Text] [Related]
2. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
Levin PA; Wei W; Zhou S; Xie L; Baser O
J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
[TBL] [Abstract][Full Text] [Related]
3. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
Rosenstock J; Nino A; Soffer J; Erskine L; Acusta A; Dole J; Carr MC; Mallory J; Home P
Diabetes Care; 2020 Oct; 43(10):2509-2518. PubMed ID: 32694215
[TBL] [Abstract][Full Text] [Related]
4. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
5. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
[TBL] [Abstract][Full Text] [Related]
6. Adding Rapid-Acting Insulin or GLP-1 Receptor Agonist to Basal Insulin: Outcomes in a Community Setting.
Dalal MR; Xie L; Baser O; DiGenio A
Endocr Pract; 2015 Jan; 21(1):68-76. PubMed ID: 25148821
[TBL] [Abstract][Full Text] [Related]
7. Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks.
Leiter LA; Gross JL; Chow F; Miller D; Johnson S; Ahrén B;
J Diabetes Complications; 2017 Aug; 31(8):1283-1285. PubMed ID: 28587789
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.
Balena R; Hensley IE; Miller S; Barnett AH
Diabetes Obes Metab; 2013 Jun; 15(6):485-502. PubMed ID: 23061470
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.
Porcellati F; Lucidi P; Bolli GB; Fanelli CG
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S16-6S20. PubMed ID: 26774015
[TBL] [Abstract][Full Text] [Related]
10. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
Levin PA; Zhou S; Gill J; Wei W
J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
[TBL] [Abstract][Full Text] [Related]
11. COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE.
Levin P; Fan T; Song X; Nero D; Davis B; Chu BC
Endocr Pract; 2017 Nov; 23(11):1316-1324. PubMed ID: 28816532
[TBL] [Abstract][Full Text] [Related]
12. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
[TBL] [Abstract][Full Text] [Related]
13. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
Yoon NM; Cavaghan MK; Brunelle RL; Roach P
Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
[TBL] [Abstract][Full Text] [Related]
14. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
Goldenberg RM; Berard L
Curr Med Res Opin; 2018 Jan; 34(1):1-10. PubMed ID: 28836861
[TBL] [Abstract][Full Text] [Related]
15. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.
Carris NW; Taylor JR; Gums JG
Drugs; 2014 Dec; 74(18):2141-52. PubMed ID: 25414121
[TBL] [Abstract][Full Text] [Related]
16. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
[TBL] [Abstract][Full Text] [Related]
17. Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.
Bailey TS; Gill J; Jones S M; Shenoy L; Nicholls C; Westerbacka J
Diabetes Obes Metab; 2022 Aug; 24(8):1617-1622. PubMed ID: 35491520
[TBL] [Abstract][Full Text] [Related]
18. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections.
Riddle MC; Rosenstock J; Vlajnic A; Gao L
Diabetes Obes Metab; 2014 May; 16(5):396-402. PubMed ID: 24118931
[TBL] [Abstract][Full Text] [Related]
19. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
Lane W; Weinrib S; Rappaport J
Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
[TBL] [Abstract][Full Text] [Related]
20. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.
Yu M; Mody R; Landó LF; Shui A; Kallenbach L; Slipski L; de Oliveira CP
Clin Ther; 2017 Dec; 39(12):2399-2408. PubMed ID: 29196084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
